文献速递免疫规划传染病防控与疫情报告

点突变Ag85B抗原提升表达量并保护小鼠抵抗结核分枝杆菌气溶胶攻击

A point-mutated Ag85B antigen improves recombinant bacterial expression and protects mice from aerosol M. tuberculosis challenge.
PubMed 文献 · Vaccine · 2026-02-02

本研究针对结核分枝杆菌Ag85B抗原在大肠杆菌中重组表达产量低的问题,利用ThermoMPNN算法预测稳定化突变,发现D52W单突变显著提高表达产量且储存稳定性良好。该突变体Ag85B-52W可通过组氨酸标签与含钴卟啉脂质体快速结合,表面蛋白保持抗原性。小鼠免疫脂质体疫苗后诱导抗原特异性抗体和T细胞应答,气溶胶结核分枝杆菌攻击后肺部细菌负荷降低。

要点

  • D52W点突变显著提高Ag85B在大肠杆菌中的表达产量并保持良好储存稳定性。
  • Ag85B-52W脂质体疫苗可诱导小鼠抗原特异性体液和细胞免疫应答。
  • 免疫后小鼠气溶胶结核分枝杆菌攻击后肺部细菌负荷降低。

核心结论

  • Ag85B的D52W点突变可改善重组表达产量,其脂质体疫苗在小鼠中诱导免疫保护并降低肺部细菌负荷。

研究设计与样本

  • 利用ThermoMPNN蛋白结构算法预测Ag85B稳定化突变,在大肠杆菌中重组表达并纯化,评估表达产量与储存稳定性。
  • 将Ag85B-52W与含钴卟啉脂质体结合制备疫苗,免疫小鼠后检测抗原特异性抗体和T细胞应答。
  • 小鼠经气溶胶结核分枝杆菌攻击后评估肺部细菌负荷。

主要发现

  • Ag85B在大肠杆菌中以组氨酸标签纯化时表达产量低。
  • D52W单突变显著提高Ag85B在大肠杆菌中的表达产量且储存稳定性良好。
  • Ag85B-52W通过组氨酸标签与含钴卟啉脂质体快速结合,抗组氨酸标签抗体反应性受抑制,而表面蛋白仍可被抗Ag85B抗体识别。
  • Ag85B-52W脂质体疫苗免疫小鼠诱导抗原特异性抗体和T细胞应答,气溶胶结核分枝杆菌攻击后肺部细菌负荷降低。

临床怎么用

  • 该点突变策略可促进重组Ag85B在结核疫苗开发中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis (TB) remains a global health problem, providing motivation for improved vaccine approaches, such as subunit vaccines targeting specific Mycobacterium tuberculosis (M. tuberculosis) antigens. Ag85B is a protein involved in cell wall biosynthesis, is abundant in M. tuberculosis culture supernatants, and has been incorporated in several TB vaccines candidates. We observed low expression yields of Ag85B when expressed recombinantly in E. coli using a histidine-tag purification approach. To address this, we utilized the ThermoMPNN protein structure algorithm to predict several stabilizing mutations in Ag85B. Of these, a single mutation, D52W, significantly enhanced expression yield in E. coli with good storage stability. Ag85B-52W exhibited rapid binding to liposomes incorporating cobalt-porphyrin via his-tag interaction, resulting in suppression in reactivity with an anti-his-tag antibody (due to anchoring of the his-tag in the bilayer), while the surface-displayed protein remained reactive towards anti-Ag85B antibodies. Immunization with Ag85B-52W in a liposomal vaccine elicited antigen-specific antibody and T cell responses, resulting in reduced lung bacterial burden in mice following aerosol M. tuberculosis challenge. SIGNIFICANCE STATEMENT: A point mutation in the M. tuberculosis Ag85B protein, predicted by ThermoMPNN algorithm, enhanced its antigen expression yield in E. coli with good storage stability. Immunization with the Ag85B mutant with a liposome vaccine system in mice resulted in antigen-specific humoral and cellular response that protected mice against M. tuberculosis infection. This approach could facilitate the use of recombinant Ag85B in TB vaccine development.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hsu WL, Jiao Y, Hvasta M, et al. A point-mutated Ag85B antigen improves recombinant bacterial expression and protects mice from aerosol M. tuberculosis challenge. Vaccine. 2026. PMID: 41633307. doi:10.1016/j.vaccine.2026.128281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。